Company Overview
About Delfi Diagnostics
Delfi Diagnostics is a biotechnology company founded in 2019 by Victor Velculescu and headquartered in Baltimore, Maryland, specializing in blood-based cancer detection using machine learning and whole-genome sequencing of cell-free DNA (cfDNA). The company''s AI platform analyzes genome-wide fragmentation patterns of cell-free DNA from a simple blood draw — a liquid biopsy — to detect cancer-associated signals across multiple cancer types. This approach, called DELFI (DNA Evaluation of Fragments for Early Interception), generates a large number of features across the entire genome that machine learning models synthesize into a cancer risk score.
Business Model & Competitive Advantage
Delfi Diagnostics has raised $332M in total funding from investors including OrbiMed, DFJ Growth, and Merck Global Health Innovation Fund, securing $34.3M in an additional round in December 2025. The company employs approximately 166 people as of early 2026. Its flagship commercial product, FirstLook Lung, is a clinically validated blood test designed to improve early detection of lung cancer — the leading cause of cancer death in the US — and to increase adherence to lung cancer screening programs. In December 2025, Hackensack Meridian Health announced a partnership with Delfi to improve lung cancer screening adherence supported by a Lilly Healthcare Improvement grant.
Competitive Landscape 2025–2026
Delfi Diagnostics is also developing DELFI-TF, a research service actively used by five top-20 pharmaceutical companies for oncology drug development, tracking treatment response through ctDNA fragmentation patterns. The company presented data at the 2025 AACR Annual Meeting on expanding its platform to additional cancer types including liver, ovarian, and others — supporting a long-term vision of a multi-cancer early detection (MCED) blood test that can screen for multiple cancer types simultaneously.
Key Differentiators
Strong Challenger
Delfi Diagnostics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Delfi Diagnostics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Delfi Diagnostics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Delfi Diagnostics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Delfi Diagnostics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →